Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product

  • End date
    Mar 20, 2024
  • participants needed
  • sponsor
    Jun Zhu
Updated on 1 March 2022
Accepts healthy volunteers


Title: Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy Subjects for the Development of Cellular Immunotherapy Product


CAR-T therapies are being developed that utilize modified immune cells to fight tumors. 'Off-the-shelf' allogeneic CAR-T technology has better efficacy and more promising clinical applications. Investigators want to use the cells of healthy subjects to perform the studies. To accomplish this, they are collecting PBMCs through apheresis.


To collect PBMCs from healthy subjects for product development for cell Immunotherapies.



Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells from donors has many potential advantages over autologous approaches, such as the immediate availability of cryopreserved batches for patient treatment, possible standardization of the CAR-T cell product, time for multiple cell modifications, redosing or combination of CAR T cells directed against different targets, and decreased cost using an industrialized process. The T cells currently used for CAR-T cell manufacturing are mainly derived from peripheral blood mono-nuclear cells (PBMCs) .The manufacture of allogeneic CAR T cells from PBMCs collected from healthy donors is associated with the ability to make multiple vials from a single apheresis product. Allogeneic CAR T cells are created from healthy donors, they are generated from immune cells that have not been impacted by the immune effects of cancer or by exposure to chemotherapeutic agents, in contrast to autologous T cells from patients. The selection of donors on the basis of their immune characteristics is likely to be a key factor in decreasing the heterogeneity of the final cell product

  • To produce allogeneic CAR T cells with different targets and other cell products by using PBMCs from healthy subjects.
  • To develop and optimize the methodology for the response or quality determination of cell Immunotherapy products.

All subjects are required to sign a written informed consent form for the study. After the signing of informed consent form, participants will be screened with a series of vital signs, physical examinations and laboratory tests. Demographic data and medical history of the subjects will also be documented. In addition, 30 mL peripheral venous blood sample will be collected to evaluate the biological characteristics of each subject. Participants will undergo a routine blood test within 24 hours before the apheresis to reconfirm their eligibility and 3-5 mL blood samples are to be drawn for the development of detection methods of cell-based immunotherapy. Subjects who meet all the inclusion criteria and do not meet any exclusion criteria are qualified to donate peripheral blood mono-nuclear cells (PBMCs) by means of apheresis. 610[9] of cells for each healthy person are preferred. 172 healthy subjects are to be enrolled through the whole study.

Condition Healthy Subject
Treatment Peripheral blood mononuclear cell apheresis
Clinical Study IdentifierNCT04295096
SponsorJun Zhu
Last Modified on1 March 2022


Yes No Not Sure

Inclusion Criteria

to 40 years of age
Male50 kg, female45 kg with 18.5 BMI 30
Subject has provided informed consent

Exclusion Criteria

Subject has respiratory diseases, circulatory system diseases, digestive system diseases, urinary system diseases, hematological system diseases, autoimmune diseases, endocrine disorders or metabolic disorders
Subject has nervous system diseases, mental illness, Creutzfeldt-Jakob disease or those with a family history, or those treated with tissue or tissue derivatives that may be derived from Creutzfeldt-Jakob infected people
Subject has chronic skin diseases, especially infectious, allergic or inflammatory systemic skin diseases
Subject has allergic diseases or recurrent allergies
Malignant tumors or health-affecting benign tumors
Twice or more times of blood pressure measurement exhibit (except for white coat hypertension): systolic blood pressure < 90 or 140 Millimeter of mercury (mm Hg), or diastolic blood pressure < 60 or 90 mm Hg, or pulse pressure < 30 mm Hg, heart rate: < 60 beats/min or >100 beats/min
Laboratory tests: hemoglobin: male <120 g/L, female <115 g/L, or liver and kidney laboratory result >1.5x upper limit of normal with clinical significant, or abnormal12-lead ECG with clinical significant, or abnormal abdominal B-mode ultrasound with clinical significant, or abnormal chest X-ray with clinical significant, and T cell detection of tuberculosis infection is over the limit or positive
Abnormal lymphocyte subset panel test result with clinical significance (Lymphs%, CD3+, CD3+CD4+, CD3+CD8+, CD3-CD16+CD56+,CD19+)
Hepatitis B surface antigen positive, hepatitis B virus (HBV) DNA positive, hepatitis B e antigen positive, hepatitis C antibody positive, Treponema pallidum antibody positive ,human immunodeficiency virus antibody positive, human T-cell lymphotrophic virus antibody positive, Epstein-Barr virus positive, or COVID-19 nucleic acid positive
Recipient of organ transplant
Received any major organ resection such as stomach, kidney, spleen and lung
Subject has transfusion-associated infectious diseases
Minor surgery within 3 months, such as appendectomy and recovered ophthalmic surgery; Major surgery within l 1 year, such as surgical treatment for gynecological benign tumors or superficial benign tumors
Pregnant, or have an abortion within l 6 months, childbirth within 1 year
Upper respiratory infection recovered within 1 week, or pneumonia recovered within 3 months
Acute pyelonephritis-recovered within 3 months, or urinary calculi onset
Injured or wound-contaminated by equipment contaminated by blood or tissue fluids, or has a tattoo within 1 year
Received whole blood and blood component transfusion within 1 year
Received the last vaccination of live attenuated vaccines such as measles, mumps, or polio within 2 weeks, or the last vaccination of rubella live vaccine, human rabies vaccine, live attenuated Japanese encephalitis vaccine within 4 weeks
Received the last vaccination of rabies vaccines after being bitten by an animal within 1 year
Received the last vaccination of antitoxin or immune serum injection within 4 weeks, or those who received the last vaccination of hepatitis B human immunoglobulin injection within 1 year
Participated in a clinical trials within 1 month; it should be discussed case by base if investigational product used
Those who are considered by the investigator as unsuitable for participating in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note